

DEPARTMENT OF HEALTH AND HUMAN SERVICES COMMUNICABLE DISEASE PREVENTION AND CONTROL

415 473 4163 T 415 473 6002 F

www.marinhhs.org/cdpc



Check List: Managing Patients who may have Novel Coronavirus (2019-nCoV)

Guidance for Marin County Clinicians Marin County Division of Public Health Jan 24, 2020

1. Identify patients who may have respiratory illness caused by 2019-nCoV

Healthcare providers should screen for travel history on all patients with potentially infectious disease, especially those with fever and acute respiratory illness. Place visible signage requesting visitors with a fever and recent international travel to notify a staff member.

- 2. Immediately isolate patients reporting fever (T >100.4°F or >38°C), lower respiratory symptoms (e.g., cough, shortness of breath), and travel to Wuhan City, China within 14 days prior to illness or close contact with an ill person with 2019-nCoV.
- Place surgical mask on patient.
- Place patient in private room with door closed (ideally, negative pressure airborne isolation room).
- 3. Implement infection control procedures for healthcare workers
- Standard precautions
- Contact precautions (gloves, gown)
- Airborne precautions (N95 mask or PAPR)
- Eye protection (goggles or face shield)
- 4. Immediately report the patient to Marin County Public Health: 415-473-4163

Public Health will advise on the next steps.

5. Collect specimens for laboratory diagnosis

See Specimen Collection instructions next page.

6. Continue medical evaluation and empiric treatment for other causes of respiratory infection or pneumonia as clinically indicated

All patients with suspected nCoV-2019 infection should also be tested for common causes of respiratory infection and pneumonia as clinically indicated. **Testing for other respiratory pathogens should not delay specimen collection for nCoV-2019 testing.**

7. Discuss plan of care with Marin County Public Health prior to discharge

Continue patient isolation and infection control procedures as above.

Specimen Collection Instructions

CDC recommends the collection of specimens from (1) the upper respiratory tract, (2) serum, and – if recommended in consultation with public health - (3) the lower respiratory tract.

1. Upper respiratory tract

• Nasopharyngeal swab <u>AND</u> oropharyngeal swab (NP/OP swab): Use a synthetic fiber swab with plastic shaft. Do not use calcium alginate swabs or swabs with wooden shafts.

<u>Nasopharyngeal:</u> insert swab into nostril parallel to the palate, leave swab in place for a few seconds to absorb secretions. Swab both nasopharyngeal areas with the same swab.

Oropharyngeal: swab the posterior pharynx, avoiding the tongue.

Place each swab into a separate sterile tube, each with 2-3 ml of viral transport media. Do <u>NOT</u> combine NP/OP swab specimens; keep swabs in separate viral transport media collection tubes. Refrigerate at 2-8°C.

OR

• Nasopharyngeal wash/aspirate or nasal aspirate: collect 2-3 mL into a sterile, leak-proof, screw-cap sputum collection cup or sterile dry container. Refrigerate at 2-8°C.

2. Serum

• Collect 1 tube (5-10 mL) of whole blood in a serum separator tube (minimum 1 mL whole blood is needed for pediatric patients). Refrigerate at 2-8°C.

3. Lower respiratory tract (if recommended in consultation with public health)

• **Sputum:** Collect sputum only if the patient is producing sputum; **do not perform sputum induction procedures**. Have the patient rinse the mouth with water and then expectorate deep cough sputum directly into a sterile, leak-proof, screw-cap sputum collection cup or sterile dry container. Refrigerate at 2-8°C.

OR

• Bronchoalveolar lavage, tracheal aspirate, or pleural fluid: 2-3 mL in a sterile, leak-proof, screw-cap sputum collection cup or sterile dry container. Refrigerate at 2-8°C.

Note: If specimens cannot be collected at the healthcare facility, do not refer the patient to another facility to obtain specimens. Instead, notify Public Health to discuss.

Specimen Handling Instructions

Upon approval by Marin Public Health, arrangements will be made for prompt transport of specimens for 2019-nCoV testing to the regional Public Health Laboratory (PHL). Use Category B infectious substance packaging instructions. The PHL will ship specimens to CDC for testing.

Do not send specimens directly to CDC or CDPH.

CDC Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Patients Under Investigation (PUIs) for 2019-nCoV: https://www.cdc.gov/coronavirus/2019-nCoV/guidelines-clinical-specimens.html

CDC Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with 2019-nCoV: https://www.cdc.gov/coronavirus/2019-nCoV/lab-biosafety-guidelines.html

• For biosafety reasons, it is <u>not</u> recommended to perform viral isolation in cell culture or initial characterization of viral agents recovered in cultures of specimens from a person under investigation for 2019-nCoV.